Targeting The GLP-1 Receptor As New Chronotherapy Against Nondipping Blood Pressure In Diabetes

靶向 GLP-1 受体作为对抗糖尿病非下降血压的新计时疗法

• 批准号: 10387235
• 负责人: Aaron Chacon
• 金额: $ 3.55万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-02 至 2024-01-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10387235
• 关键词: Agonist; Anti-Inflammatory Agents; Atherosclerosis; Biochemical; Blood Glucose; Blood Pressure; Blood Vessels; Characteristics; Chronic; Chronotherapy; Circadian Rhythms; Clinical Trials; Data; Diabetes Mellitus; Diabetic mouse; Disease; Diurnal Rhythm; Eating; Food; Functional disorder; Funding; Future; GLP-I receptor; Genes; Glucose; Glycosylated hemoglobin A; Goals; Guidelines; Half-Life; Health; Hour; Impairment; In Situ; Individual; Ingestion; Insulin; Kidney Diseases; Knockout Mice; Lead; Light; Measurement; Measures; Metabolic; Metabolism; Molecular; Monitor; Mus; Muscle Contraction; Non-Insulin-Dependent Diabetes Mellitus; Organ; Outcome; Pancreas; Pattern; Pharmacology; Phase; Phenotype; Physiological; Positioning Attribute; Prevalence; Property; Proteins; Recording of previous events; Reporting; Research; Resistance; Rest; Retinal Diseases; Reverse Transcriptase Polymerase Chain Reaction; Risk; Risk Factors; Role; Satiation; Series; Signal Pathway; Signal Transduction; Sleep; Smooth Muscle; Stroke; Structure; Testing; Time; Training; Type 2 diabetic; Vascular Diseases; Vascular Smooth Muscle; Western Blotting; blood glucose regulation; blood pressure elevation; blood pressure reduction; blood pressure regulation; carbohydrate metabolism; cardioprotection; circadian; db/db mouse; design; diabetic; diabetic patient; exenatide; experimental study; glucagon-like peptide 1; improved; in vivo; indexing; mortality; mouse Cre recombinase; mouse model; novel; pleiotropism; response; restoration

ABSTRACT In healthy individuals, blood pressure (BP) is 10-20% lower during the sleep period than daytime levels. Chronic disruption in this day-night pattern has shown to be an independent risk factor for type 2 diabetes (T2DM), atherosclerosis, stroke, kidney disease, retinopathy, and more. These risks increase the less BP dips, with the most severe phenotype being reverse dipping – a pattern characterized by increased BP during the sleep period over daytime levels. Vascular complications are invariably associated with T2DM with prevalence rates of nondipping BP observed as high as 73%. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as effective glucose-lowering therapy, with a diverse range of half-lives, for type 2 diabetics. But because the GLP-1 receptor (GLP-1R) is widespread, GLP-1 RAs have shown to have a multitude of beneficial effects independent of their glucose-lowering properties. Inhibition of food intake, anti-inflammatory properties, and reduction in BP are among them. My preliminary data demonstrates a clear restoration in BP's rhythm in a diabetic mouse model when the short half-life GLP-1 RA, exenatide, is administered at the onset of the light phase and its rhythm exacerbated when administered at the onset of the dark. Coinciding with this, is a restoration or worsening in food intake's diurnal rhythm. Currently, FDA guidelines consider exenatide's administration timing only in the context of glucose-lowering. The goal of this proposal is to investigate if, and how, restoration of BP rhythm lends to improvement in vascular contractility and structure. Additionally, the long half-life GLP-1 RA, semaglutide, will be explored on these parameters. Moreover, a novel smooth muscle- specific GLP-1R knockout mouse model will be generated to determine the GLP-1R's role in vascular smooth muscle hyper-reactivity, characteristic in type 2 diabetes. I hypothesize that timed administration of GLP-1 RAs will correct disruptions in circadian rhythm of BP, which will lead to healthier vascular functioning in diabetic mice. With a rich history in circadian and vascular research, my lab is uniquely positioned to carry out and test everything proposed. Funding of this proposal will not only provide me with exceptional training in biochemical, molecular, physiological, and pharmacological experimentation, but also potentially offer a novel chronotherapeutic approach to improve these, and other GLP-1 RA's, usage in the treatment of T2DM.

抽象的 在健康的个体中，血压（BP）在睡眠期间的日间水平降低了10-20％。 在这一天晚上的顾客中，慢性破坏已证明是2型Diabes的独立危险因素 （T2DM），动脉粥样硬化，中风，肾脏疾病，视网膜病等。 最严重的表型是反向浸入 - 这种模式为以您期间的BP增加为特征 白天的睡眠时间与T2DM相关 非胰甘蓝样肽-1（GLP-1）受体激动剂（RAS）观察到的非BP速率高达73％ 对于2型糖尿病患者而言，出现了有效的降血糖疗法，具有多种半衰期 由于GLP-1受体（GLP-1R）广泛，因此GLP-1 RAS已证明具有多种有益的 与降低葡萄糖的特性无关的作用。 我的初步数据中的bp降低。 糖尿病小鼠模型在短的半衰期GLP-1 ra（在光线下）给药时 当在黑暗的开始时施用相位的相位及其节奏加剧。 目前，食物摄入量的昼夜节奏恢复或恶化。 管理时间仅在降糖的背景下。 BP节奏的恢复如何改善血管收缩和结构 semaglutide将探索长期寿命的GLP-1 RA。 Specific GLP-1R Knockout MOUSE MODEL WILL WILL WILL WILL WILL WILL BE GENERATED TO DETERMINE THE GLP-1R'S Role in Vascular Smooth 肌肉超反应性，2型糖尿病的特征。 将以BP的昼夜节律腐败，这将导致糖尿病的健康功能 我的实验室有着悠久的历史。 一切都支撑了这项提案，没有主导我 分子，生理学和药理学实验，但也有效地提供了新颖的 改进这些改进这些方法